Conferences - Results from #40

AUA 2025: State-of-the-Art Lecture: Urothelial Markers April 28, 2025

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up April 28, 2025

AUA 2025: A Wearable Optical System for Monitoring Neurogenic Bladder: Tracking Volume and Pressure as a Means of Lessening the Risks of Incontinence and Autonomic Dysreflexia Following Spinal Cord Injury. April 28, 2025

AUA 2025: Case Discussions in NMIBC: Sequencing Therapy after BCG Failures April 28, 2025

AUA 2025: Oncologic Outcomes and Conditional Survival of Patients Receiving Metastases-Directed Therapy for Prostate Cancer Recurrence After Radical Prostatectomy Detected by a Positive PSMA PET April 28, 2025

AUA 2025: Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma April 28, 2025

AUA 2025: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer: ENLIGHTED Phase 3 Study April 27, 2025

AUA 2025: Long-Term Outcomes of Treatment of Recurrent or New-Onset Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel April 27, 2025

AUA 2025: Whitmore Lecture: The Evolving Role of Surgery for Bladder Cancer - The Surgeon can Make a Difference April 27, 2025

AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma April 27, 2025

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting April 27, 2025

AUA 2025: 225Ac-J591 PSMA-Targeted Radionuclide Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with Prior 177Lu-PSMA Therapy April 27, 2025

AUA 2025: Performance of Minimal Residual Disease Detection with Urine-Derived DNA in High-Grade Bladder Cancer Patients Undergoing Recommended Repeat Transurethral Resection April 27, 2025

AUA 2025: Real-World Time-to-Next-Treatment and Time-to-Castration-Resistance Among Patients with mCSPC Using ARPIs with and without Homologous Recombination Repair Alterations April 27, 2025

AUA 2025: Who Still Needs a Lymph Node Dissection with a Negative PSMA-PET? Results from the Michigan Urological Surgery Improvement Collaborative April 27, 2025

AUA 2025: COBRA: Assessment of 64Cu-SAR-bisPSMA and Standard of Care Prostate-Specific Membrane Antigen Positron Emission Tomography in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy April 27, 2025

AUA 2025: Early Oncological Outcomes of Very High-Risk Prostate Cancer Patients According to the STAMPEDE Trial Definition in the PSMA-PET Era: Implication for the Selection of the Optimal Surgical Candidate April 27, 2025

AUA 2025: Prostate Cancer Risk Groups by PSMA-PET PROMISE: Results from an International Multi-Center Registry Study April 27, 2025

AUA 2025: Impact of Timing of Recurrence on Survival Outcomes: Implications for Postoperative Management in a KEYNOTE-564 Population April 27, 2025

AUA 2025: An Update on QUILT-3.032: Complete Responses to N-803 plus BCG Therapy in BCG-Unresponsive Bladder Carcinoma In Situ (CIS) with or without Ta/T1 Papillary Disease April 27, 2025

Page 3 of 621